Prospective evaluation of a D-optimal designed population pharmacokinetic study

被引:55
作者
Green, B [1 ]
Duffull, SB [1 ]
机构
[1] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia
关键词
pharmacokinetics; population analysis; D-optimal design; enoxaparin;
D O I
10.1023/A:1024467714170
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recently, methods for computing D-optimal designs for population pharmacokinetic studies have become available. However there are few publications that have prospectively evaluated the benefits of D-optimality in population or single-subject settings. This study compared a population optimal design with an empirical design for estimating the base pharmacokinetic model for enoxaparin in a stratified randomized setting. The population pharmacokinetic D-optimal design for enoxaparin was estimated using the PFIM function (MATLAB version 6.0.0.88). The optimal design was based on a one-compartment model with lognormal between subject variability and proportional residual variability and consisted of a single design with three sampling windows (0-30 min, 1.5-5 hr and 11 - 12 hr post-dose) for all patients. The empirical design consisted of three sample time windows per patient from a total of nine windows that collectively represented the entire dose interval. Each patient was assigned to have one blood sample taken from three different windows. Windows for blood sampling times were also provided for the optimal design. Ninety six patients were recruited into the study who were currently receiving enoxaparin therapy. Patients were randomly assigned to either the optimal or empirical sampling design, stratified for body mass index. The exact times of blood samples and doses were recorded. Analysis was undertaken using NONMEM (version 5). The empirical design supported a one compartment linear model with additive residual error, while the optimal design supported a two compartment linear model with additive residual error as did the model derived from the full data set. A posterior predictive check was performed where the models arising from the empirical and optimal designs were used to predict into the full data set. This revealed the "optimal'' design derived model was superior to the empirical design model in terms of precision and was similar to the model developed from the full dataset. This study suggests optimal design techniques may be useful, even when the optimized design was based on a model that was misspecified in terms of the structural and statistical models and when the implementation of the optimal designed study deviated from the nominal design.
引用
收藏
页码:145 / 161
页数:17
相关论文
共 19 条
[1]  
Atkinson A.C., 1992, OPTIMUM EXPT DESIGNS
[2]  
Beal SL., 1992, NONMEM USERS GUIDE 5
[3]   INCORPORATING PRIOR PARAMETER UNCERTAINTY IN THE DESIGN OF SAMPLING SCHEDULES FOR PHARMACOKINETIC PARAMETER-ESTIMATION EXPERIMENTS [J].
DARGENIO, DZ .
MATHEMATICAL BIOSCIENCES, 1990, 99 (01) :105-118
[4]   OPTIMAL SAMPLING TIMES FOR PHARMACOKINETIC EXPERIMENTS [J].
DARGENIO, DZ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1981, 9 (06) :739-756
[5]   A PROSPECTIVE EVALUATION OF OPTIMAL SAMPLING THEORY IN THE DETERMINATION OF THE STEADY-STATE PHARMACOKINETICS OF PIPERACILLIN IN FEBRILE NEUTROPENIC CANCER-PATIENTS [J].
DRUSANO, GL ;
FORREST, A ;
PLAISANCE, KI ;
WADE, JC .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (06) :635-641
[6]   The use of simulated annealing for finding optimal population designs [J].
Duffull, SB ;
Retout, S ;
Mentré, F .
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2002, 69 (01) :25-35
[7]  
Girard P, 1998, STAT MED, V17, P2313, DOI 10.1002/(SICI)1097-0258(19981030)17:20<2313::AID-SIM935>3.0.CO
[8]  
2-V
[9]  
GREEN B, 2003, IN PRESS BR J CLIN P
[10]  
Laposata M, 1998, ARCH PATHOL LAB MED, V122, P799